Loading...
The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma.
Forker, Laura-Jane Gaunt, P Sioletic, S Shenjere, Patrick Potter, Robert Roberts, Darren L Irlam, Joely J Valentine, Helen R Hughes, D Hughes, A
Forker, Laura-Jane
Gaunt, P
Sioletic, S
Shenjere, Patrick
Potter, Robert
Roberts, Darren L
Irlam, Joely J
Valentine, Helen R
Hughes, D
Hughes, A
Citations
Altmetric:
Abstract
Despite high metastasis rates, adjuvant/neoadjuvant systemic therapy for localised soft tissue sarcoma (STS) is not used routinely. Progress requires tailoring therapy to features of tumour biology, which need exploration in well-documented cohorts. Hypoxia has been linked to metastasis in STS and is targetable. This study evaluated hypoxia prognostic markers in the phase III adjuvant radiotherapy VorteX trial.
Description
Date
2017-12-12
Publisher
Collections
Files
Keywords
Type
Article
Citation
The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma. 2017 Br J Cancer